August 1, 2017
Transgene testing Opdivo with Pexa-Vec to treat HCC – first patient treated
Transgene has treated the first patient in a Phase 1/2 clinical trial for the combination of Pexa-Vec with Opdivo as a first-line treatment of advanced hepatocellular carcinoma (HCC). The trial will assess the safety and tolerability as well as the anti-tumor activity and efficacy of this immunotherapy combination regimen in up to 36 patients (NCT03071094). This tumour accounts for approximately 75% of liver cancers.